• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Deep Lens Lands $14M to Scale AI-Driven Digital Pathology Platform

by Fred Pennic 04/08/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Digital Pathology Startup Deep Lens Nabs $14M to Expand AI Pathology Platform for Clinical Trial Recruitment
Digital pathology startup Deep Lens lands $14M in Series A funding to scale AI-driven digital pathology platform

Deep Lens, Inc., a Columbus, OH-based AI-driven digital pathology company focused on clinical trial recruitment at the time of diagnosis has raised $14 million in Series A funding. The Series A round was led by Northpond Ventures with participation from existing investors Rev1 Ventures, Sierra Ventures, and Tamarind-Hill Partners. The funding comes months after Deep Lens emerged from stealth in October 2018 with a $3.2M seed round, which brings their funding to date total to $17.5 million.

Built by Pathologists for Pathologists

Founded by Dave Billite and Simon Arkell, Deep Lens’ digital pathology platform was developed by the innovation group at Nationwide Children’s Hospital (NCH) in Columbus, Ohio. The platform was built by expert pathology groups working with the NCH team from around the world that focused on specific tumor types and subtypes. NCH played the role of global biospecimen repository and facilitated research projects globally including The Cancer Genome Atlas Project (TCGA) before being commercialized. Those participants, at over 65 major institutions, helped forge the requirements that today make up the company’s flagship technology called VIPER (Virtual Imaging for Pathology Education and Research).

Rapid Central Pathology Review for Patient Enrollment

Patient recruitment for clinical trials remains a time-intensive, costly barrier to the execution of drug development programs. More than 14,000 oncology clinical trials are actively recruiting patients yet estimates put the rate of participation as low as three percent of potential trial candidates. Deep Lens’ VIPER  subscription-based platform combines artificial intelligence (AI) with advanced pathology workflows to enable the pathologist in clinical trial recruitment. By identifying eligible patients at the time of their diagnosis, much sooner than current methods, VIPER can help fast-track trial enrollment and potentially shorten the duration of the trial.

Digital Collaboration

VIPER Enterprise is available for case assignment, collaboration between team members for second opinions, and group reviews of difficult cases. The platform is free and includes 100GB per pathologist of free cloud storage. After reaching 100GB in cloud storage, the user will pay a simple monthly fee. Deep Lens plans to roll out single user accounts for pathologists to collaborate on any case with a pathologist outside of their organization in the near future.

Other use cases for the VIPER platform includes lab as a service (whole side imaging/scanning service), biospecimen quality control, quality assurance, and training/education.

Expansion Plans for Deep Lens

Deep Lens will use the funding to further expand its artificial intelligence (AI) and platform product development activities and scale its service, sales, and marketing organizations to support current and anticipated demand and growth for its VIPER platform to support to clinical trial recruitment.

“Since our inception, we’ve benefitted from a tremendous group of investors, which now includes the world class team at Northpond Ventures,” said Deep Lens co-founder and CEO Dave Billiter. “This Series A financing is further validation of the value of our industry-changing approach to digital pathology in delivering the right cancer diagnoses faster and accelerating oncology trial recruitment and timelines.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, Artificial Intelligence, Artificial Intelligence (AI) Software Platform, cancer, Clinical Trial, Clinical Trial Recruitment, Clinical Trials, cloud, Deep Lens, Digital Pathology, Oncology, Partners

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |